In a cohort of 185,066 patients with type 2 diabetes, GLP-1 receptor agonists were linked to a modestly higher risk of incident diabetic retinopathy (HR 1.07 ) but not to NAION. Among patients with preexisting DR, GLP-1 RAs did not accelerate progression to proliferative DR or macular oedema and were associated with fewer sight-threatening events, including vitreous haemorrhage, neovascular glaucoma, and blindness. These results highlight the importance of ongoing ophthalmic monitoring in all GLP-1 RA–treated patients. To read more; Click here Do GLP-1 RAs change how we monitor DR risk in diabetes care?
##Reference## Ramsey DJ, Makwana B, Dani SS, Patel M, Panchal K, Shah J, Khadke S, Kumar A, Patel T, Kosiborod MN, Fonarow GC, Ramsey KM, Nohria A, Butler J, Ganatra S. GLP-1 Receptor Agonists and Sight-Threatening Ophthalmic Complications in Patients With Type 2 Diabetes. JAMA Netw…
